Compounded vs. Commercial Ketamine Troches: Understanding the Difference

Overview

When patients begin ketamine troche therapy, they often wonder whether they are receiving a standardized, factory-made product or something custom-prepared. The answer, in nearly all cases, is the latter: ketamine troches are compounded by specialty pharmacies rather than mass-produced by pharmaceutical manufacturers.

This distinction matters because compounded products and commercially manufactured products exist under different regulatory frameworks, quality standards, and consistency expectations. Understanding these differences empowers patients to ask informed questions about the troches they receive. Our compounding pharmacy guide explains what to look for when evaluating a pharmacy, and our article on how troches are compounded walks through the manufacturing process.

Why Ketamine Troches Are Compounded

Ketamine itself is FDA-approved — it has been on the market since 1970 as an anesthetic agent. However, the FDA approved ketamine in injectable formulations for anesthesia, not as sublingual troches for depression, anxiety, or chronic pain.

No pharmaceutical manufacturer has sought (or received) FDA approval for a ketamine troche product. The reasons are primarily economic:

• The patent on ketamine expired decades ago, meaning any company's investment in expensive FDA clinical trials could be undermined by generic competition
• The off-label market for compounded ketamine is already well-established
• The FDA approval process for a new formulation of an existing drug (a 505(b)(2) pathway) still requires substantial clinical trial data and investment

As a result, ketamine troches exist exclusively in the compounded space — prepared by licensed compounding pharmacies on a per-prescription basis.

What Compounding Means

The Compounding Process

A compounding pharmacy receives a prescription from a licensed prescriber specifying:

• Ketamine dose (e.g., 200 mg per troche)
• Quantity (e.g., 30 troches)
• Formulation preferences (hard candy base, soft lozenge, rapid dissolve)
• Flavoring (mint, cherry, grape, unflavored)

A pharmacist then prepares the troches according to this prescription, combining pharmaceutical-grade ketamine hydrochloride powder with a troche base material, flavoring agents, and any other specified excipients. The troches are individually formed, packaged, labeled, and dispensed.

Regulatory Framework

Compounding pharmacies in the United States operate under two primary regulatory categories:

503A pharmacies: Traditional compounding pharmacies that prepare medications based on individual prescriptions. Regulated primarily by state boards of pharmacy. They cannot produce large batches without patient-specific prescriptions.

503B outsourcing facilities: Registered with the FDA and subject to FDA inspection. These facilities can produce larger quantities in advance of prescriptions, operating under current Good Manufacturing Practices (cGMP) standards similar to (but not identical to) pharmaceutical manufacturers.

The regulatory oversight is meaningful. 503B facilities provide an additional layer of quality assurance through FDA registration and inspection, while 503A pharmacies rely primarily on state-level oversight, which varies in rigor.

Quality and Consistency Considerations

Potency and Uniformity

A core concern with compounded products is whether each troche contains the amount of ketamine specified on the label. Unlike commercially manufactured tablets that undergo extensive batch testing and FDA-enforced potency standards, compounded troches have more variable quality assurance:

Well-run pharmacies perform potency testing, content uniformity testing, and beyond-use dating studies. They follow USP (United States Pharmacopeia) chapters 795 (non-sterile compounding) and 797 (sterile compounding, if applicable) standards.

Less rigorous pharmacies may not perform routine potency verification, relying instead on the accuracy of their compounding process alone.

Patients cannot easily distinguish between these quality levels. Asking your provider which pharmacy they use and why — and whether that pharmacy holds PCAB (Pharmacy Compounding Accreditation Board) accreditation — is a reasonable and important question.

Formulation Variability

Because troches are compounded, formulations vary between pharmacies:

• Base material: Some use hard candy bases (slower dissolution, longer mucosal contact), others use softer gelatin-based lozenges (faster dissolution), and some offer rapid-dissolve tablet (RDT) formulations
• Flavoring: Options range from mint and berry to citrus and bubblegum, with varying effectiveness at masking ketamine's bitter taste
• pH: The pH of the troche formulation affects both ketamine stability and absorption efficiency. Some pharmacies optimize pH for sublingual absorption; others may not
• Size and shape: Troches range from small disc-shaped lozenges to larger cone or cylinder shapes

These variations can produce meaningfully different patient experiences — one pharmacy's troches might dissolve in 10 minutes while another's take 30 — even at the same dose.

Beyond-Use Dating (Expiration)

Compounded troches are assigned beyond-use dates (BUDs) rather than expiration dates. BUDs are typically more conservative than manufactured product expiration dates:

• Common BUD: 90-180 days from compounding
• Some pharmacies assign shorter BUDs (30-60 days) if stability data is limited

Proper storage according to the pharmacy's instructions is essential to maintain potency through the BUD period.

What Would a Commercial Product Look Like?

If a manufacturer were to develop an FDA-approved ketamine troche, it would likely feature:

• Rigorous clinical trial data supporting specific indications and doses
• Standardized formulation with verified dissolution rates
• Strict potency and uniformity testing for every batch
• FDA-enforced Good Manufacturing Practices
• Package insert with detailed prescribing information
• Post-market surveillance and adverse event reporting requirements
• Insurance coverage potential

Until such a product exists, compounded troches remain the only option. This is not inherently problematic — compounding is a legitimate and necessary part of pharmaceutical care — but patients should understand what they are receiving.

How to Evaluate Your Compounding Pharmacy

Questions to ask your provider or pharmacy:

1. Is the pharmacy PCAB-accredited? PCAB accreditation indicates voluntary adherence to quality standards beyond minimum legal requirements
2. Does the pharmacy follow USP 795 standards? This is the baseline standard for non-sterile compounding
3. Does the pharmacy perform potency testing on ketamine troche batches? Reputable pharmacies test batches for ketamine content
4. What is the beyond-use date? Longer BUDs typically indicate the pharmacy has stability data supporting their formulation
5. Is the pharmacy a 503A or 503B facility? 503B facilities have additional FDA oversight
6. What base material is used? Understanding the formulation helps set expectations for dissolution and experience
7. Can you request a specific formulation or flavor? Good pharmacies accommodate reasonable patient preferences

Cost Comparison

Compounded troche pricing varies by pharmacy, dose, and geographic region:

• Per troche: $1-15 (higher doses and specialty formulations cost more)
• Monthly supply: $60-400 (depending on dose and frequency)
• Shipping: Most pharmacies offer overnight or priority shipping; costs vary

Because there is no commercial product, there is no "retail price" benchmark. Patients benefit from comparing prices across pharmacies, though the cheapest option is not always the best if quality standards are lower.

Key Takeaways

• Nearly all ketamine troches are compounded by specialty pharmacies, not mass-manufactured.
• Compounding is a legitimate pharmaceutical practice regulated by state boards and, for 503B facilities, the FDA.
• Quality, potency, and consistency vary between compounding pharmacies — accreditation and testing standards matter.
• Formulation differences (base material, flavoring, pH) between pharmacies can affect patient experience and absorption.
• Patients should ask about their pharmacy's accreditation, testing practices, and quality standards.
• No commercially manufactured, FDA-approved ketamine troche product currently exists.

References

• USP Chapter 795: Pharmaceutical Compounding — Nonsterile Preparations — United States Pharmacopeia standards for non-sterile compounding quality
• StatPearls: Ketamine — Comprehensive clinical reference on ketamine including formulation and regulatory status
• FDA: Compounding and the FDA — U.S. Food and Drug Administration overview of drug compounding regulation and oversight
• PubChem: Ketamine Compound Summary — NCBI chemical database entry for ketamine hydrochloride including stability and formulation data